MedGenome announced that Sam Santhosh, co‐founder and currently Chairman and Chief Executive Officer, will transition from his executive leadership role and move to the company’s Board of Directors. Mahesh Pratapneni, who co‐founded MedGenome with Santhosh, and has been the Chief Strategy Officer, will take over as Group CEO. 

Dr Felix Olale, Partner of LeapFrog Investments, who has served as a Board member after leading a $55 million investment into MedGenome in 2020, has been appointed Chairman of the Board of Directors. 

Santhosh said, "The covid pandemic has further highlighted the importance of genomics and population genetics. I am hoping to work closely with the government of my home state of Kerala to enhance the government’s initiatives in this area. I have recently taken on an Advisory role in K‐DISC (Kerala Development and Innovation Strategy Council) and joined the Governing body of the Kerala Startup Mission to support entrepreneurs.”  

Incoming Group CEO Pratapneni has been with MedGenome since its inception. Continuing to work with him will be India and South Asia CEO, Dr Vedam Ramprasad, whose strong industry and scientific knowledge have been instrumental in scaling the business and building strategic partnerships; Dr Sekar Seshagiri, CSO, who brings more than two decades of genomics research experience; and CFO Surajit Chakrabartty, who has been responsible for managing the financial growth of the company. 

Pratapneni said, “We now see incredible potential for genomic medicine to democratize access to these innovations and improve the prospects of drug discovery in low‐ and middle‐income countries across South Asia, Africa and the Middle East."